In order to obtain maximal DNA and PCR yields, several modifications to the standard DNA extraction procedure was made to both kits. The Puregene extraction was modified by extending the Proteinase digestion overnight, as well as holding the isopropanol and ethanol washes at 20°C for at least 1 h and 30 min, respectively. These changes lengthened the time necessary for each extraction. The Qiagen extraction was modified by adding an additional 5 min spin after the AW2 wash. The second spin removed any remaining alcohol that might inhibit subsequent PCR assays. This change did not significantly change the time necessary for DNA extraction. While both extraction protocols are relatively simple, the Puregene protocol was more labor intensive and may have a higher chance of contamination/DNA loss, as the isopropanol and ethanol washes both require decanting of the washing solution. These differences may make the Puregene kit less amenable to a high throughput DNA extraction process.
In summary, both the Puregene and Qiagen kits yield DNA of adequate quantity and purity of PCR-based genotyping. If maximal DNA yields are required, the Puregene kit may provide higher DNA yields. However, the Qiagen extraction requires less time and is technically easier. Thus, if multiple bone marrow aliquots or slides are available on a subject, then the Qiagen kit may provide a faster and more uniform DNA extraction. Although TMD usually regresses spontaneously in most patients, some patients subsequently develop acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) months or years later.
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1,2 Almost all these AML patients are diagnosed as having acute megakaryoblastic leukemia (AMKL). 1, 2 Recently, mutations of the AML1/RUNX1 gene were found in leukemia, 3, 4 MDS, 5 and familial thrombocythemia with a propensity to develop AML, 6, 7 but not in chronic myelogenous leuke- mia. 8 All mutations were concentrated in the runt domain of AML1 and the function of most mutants was decreased or lost. 3, 5 A high incidence of mutations in AML1 in myeloid malignancies with acquired trisomy 21 4 prompted us to examine TMD, AML and MDS in children with DS.
We analyzed mutations in the runt domain of AML1 by polymerase chain reaction (PCR) or reverse transcriptase (RT)-PCR-single-strand conformation polymorphism (SSCP) in 46 pediatric DS patients with hematological malignancies (Table 1 ). The primers used for these analyses were the same as previous reports. 5, 6 The PCR reagent and amplification was made according to previous reports 5, 6 with some modifications. PCR products showing an abnormal band shift in SSCP were sequenced in both directions to confirm mutations.
No mutations were found in 45 DS patients, only one TMD patient showed a heterozygous missense mutation at codon 58 (CAC to AAC) (Figure 1) , which leads to an amino acid change, H58N. This patient was a female born at 38 weeks of gestational age, weighing 2795 g. Hepatosplenomegaly and umbilical hernia were revealed after birth. This DS patient was diagnosed as having TMD 5 days after birth. Initial white blood cell (WBC) count was 57 200/l with 20% blasts, AUL, acute undifferentiated leukemia.
Figure 1
Mutation of the AML1 gene in a Down syndrome patient with TMD. A nucleotide change is apparent when compared to an unaffected sample. The position of the changed nucleotide is indicated by arrows and underlines.
Hb was 15.0 g/dl and platelet count was 277 000/l. Chromosomal analysis of BM cells at diagnosis showed 47, XX, +21 in eight cells, 48, XX, +21, +21 in four cells, and 49, XX, +21, +21, +22 in nine cells. Although she was not treated, her WBC gradually decreased within 2 months. Five months after birth, although she suffered from thrombocytopenia due to an unknown viral infection, her platelet count spontaneously recovered to within the normal range. She died suddenly 12 months after birth. It is not known whether she developed AML.
No mutations of AML1 have so far been reported in three DS patients, including two acute lymphoblastic leukemias and one AML. 4 Our results, combined with the previous report, suggest that the AML1 mutation is rarely found in DS, and the mutation does not play a significant role in the development of hematological disorders in DS. The mutation found in one TMD patient was the same mutation (H58N) as that reported in an adult patient with AML-M0. 3 Unlike most other mutants of AML1, H58N was virtually normal in DNA binding and heterodimerization activities, but was demonstrated to cause a hypernormal activation of the M-CSF receptor promoter. 3 Importantly, H58 residue is perfectly conserved in several species.
3
H58N is considered to play a role in the leukemogenesis of AML through an aberrant up-regulation of an AML1-target. 3 Chromosomal analysis of this TMD patient with DS showed tetrasomy 21 in 13 of 21 cells at diagnosis. In general, clonal chromosomal abnormalities are not found in DS patients with TMD. 1 TMD blasts in DS patients rarely have clonal cytogenetic abnormalities, including tetrasomy 21, t(21;21) and i(21q). 2 All these abnormalities include acquired chromosome 21 in addition to constitutional trisomy 21. AML1 mutations are frequently found in myeloid malignancies with acquired trisomy 21. 4 Our results suggest that the AML1 mutation found in one TMD patient is associated with acquired chromosome 21 in addition to constiLeukemia tutional trisomy 21. Further studies are needed to clarify whether or not this abnormal clone might evolve into AMKL.
